-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Icosavax (NASDAQ:ICVX)
Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) & Icosavax (NASDAQ:ICVX)
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Profitability
This table compares Tarsus Pharmaceuticals and Icosavax's net margins, return on equity and return on assets.
Get Tarsus Pharmaceuticals alerts:Net Margins | Return on Equity | Return on Assets | |
Tarsus Pharmaceuticals | -324.99% | -31.56% | -28.14% |
Icosavax | -1,326.23% | -35.68% | -34.24% |
Valuation & Earnings
This table compares Tarsus Pharmaceuticals and Icosavax's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tarsus Pharmaceuticals | $57.03 million | 7.78 | -$13.83 million | ($2.70) | -6.16 |
Icosavax | $7.80 million | 37.79 | -$66.97 million | ($2.93) | -2.53 |
Insider and Institutional Ownership
70.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.4% of Icosavax shares are owned by institutional investors. 33.1% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 39.1% of Icosavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings for Tarsus Pharmaceuticals and Icosavax, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tarsus Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Icosavax | 0 | 0 | 4 | 0 | 3.00 |
Tarsus Pharmaceuticals currently has a consensus target price of $52.75, suggesting a potential upside of 217.01%. Icosavax has a consensus target price of $37.90, suggesting a potential upside of 410.78%. Given Icosavax's higher probable upside, analysts clearly believe Icosavax is more favorable than Tarsus Pharmaceuticals.
Summary
Tarsus Pharmaceuticals beats Icosavax on 8 of the 14 factors compared between the two stocks.
About Tarsus Pharmaceuticals
(Get Rating)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Icosavax
(Get Rating)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
塔尔苏斯制药(纳斯达克:TARS-GET Rating)和艾柯萨克斯(纳斯达克:ICVX-GET Rating)都是小盘医疗公司,但哪只股票更好?我们将根据这两家公司的收益、风险、估值、机构所有权、盈利能力、分析师建议和股息的实力进行比较。
Profitability
盈利能力
This table compares Tarsus Pharmaceuticals and Icosavax's net margins, return on equity and return on assets.
此表比较了Tarsus制药公司和ICosavax公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Tarsus Pharmaceuticals | -324.99% | -31.56% | -28.14% |
Icosavax | -1,326.23% | -35.68% | -34.24% |
净利润率 | 股本回报率 | 资产回报率 | |
塔尔苏制药公司 | -324.99% | -31.56% | -28.14% |
伊科萨克斯 | -1,326.23% | -35.68% | -34.24% |
Valuation & Earnings
估值与收益
This table compares Tarsus Pharmaceuticals and Icosavax's gross revenue, earnings per share (EPS) and valuation.
该表格比较了塔尔苏斯制药公司和ICosavax的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Tarsus Pharmaceuticals | $57.03 million | 7.78 | -$13.83 million | ($2.70) | -6.16 |
Icosavax | $7.80 million | 37.79 | -$66.97 million | ($2.93) | -2.53 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
塔尔苏制药公司 | 5,703万美元 | 7.78 | -1,383万美元 | ($2.70) | -6.16 |
伊科萨克斯 | 780万美元 | 37.79 | -6,697万元 | ($2.93) | -2.53 |
Insider and Institutional Ownership
内部人与机构持股
70.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.4% of Icosavax shares are owned by institutional investors. 33.1% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 39.1% of Icosavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
塔尔苏斯制药公司70.0%的股份由机构投资者持有。相比之下,Icoavax 79.4%的股份由机构投资者持有。塔尔苏斯制药公司33.1%的股份由公司内部人士持有。相比之下,Icoavax 39.1%的股份由公司内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票的长期表现将好于大盘。
Analyst Recommendations
分析师建议
This is a summary of current ratings for Tarsus Pharmaceuticals and Icosavax, as reported by MarketBeat.com.
这是MarketBeat.com报道的Tarsus PharmPharmticals和ICosavax的当前评级摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Tarsus Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Icosavax | 0 | 0 | 4 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
塔尔苏制药公司 | 0 | 0 | 3 | 1 | 3.25 |
伊科萨克斯 | 0 | 0 | 4 | 0 | 3.00 |
Tarsus Pharmaceuticals currently has a consensus target price of $52.75, suggesting a potential upside of 217.01%. Icosavax has a consensus target price of $37.90, suggesting a potential upside of 410.78%. Given Icosavax's higher probable upside, analysts clearly believe Icosavax is more favorable than Tarsus Pharmaceuticals.
Tarsus PharmPharmticals目前的共识目标价为52.75美元,暗示潜在上行217.01%。Icoavax的普遍目标价为37.9美元,暗示潜在上涨410.78%。考虑到ICosavax更有可能的上行空间,分析师们显然认为ICosavax比Tarsus PharmPharmticals更有利。
Summary
摘要
Tarsus Pharmaceuticals beats Icosavax on 8 of the 14 factors compared between the two stocks.
Tarsus PharmPharmticals在两只股票之间进行比较的14个因素中,有8个超过了Icoavax。
About Tarsus Pharmaceuticals
关于塔尔苏制药公司
(Get Rating)
(获取评级)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
塔尔苏斯制药公司是一家临床阶段的生物制药公司,专注于眼科疾病的新型候选治疗药物的开发和商业化。它的主要候选产品是TP-03,这是一种新的治疗方法,处于第三阶段,用于治疗蠕形螨感染引起的眼缘炎,以及治疗眉毛腺疾病。该公司还在开发用于治疗酒渣鼻的TP-04和用于莱姆预防和社区减少疟疾的TP-05。此外,该公司还开发了洛替兰,用于治疗人类医学中各种疾病,包括眼睛护理、皮肤病和其他疾病。塔尔苏斯制药公司成立于2016年,总部设在加利福尼亚州欧文。
About Icosavax
关于ICosavax
(Get Rating)
(获取评级)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
ICosavax,Inc.是一家生物制药公司,开发针对传染病的疫苗。该公司在其病毒样颗粒(VLP)平台技术的帮助下,主要专注于威胁生命的呼吸道疾病。该公司正在筹备的产品包括IVX-121,一种以RSV为靶标的候选疫苗,正处于1/1b期临床试验;IVX-A12,一种具有RSV/人偏肺病毒(HMPV)二价靶标的呼吸道合胞病毒(RSV)单价抗原候选;IVX-241,一种以hMPV为靶标的疫苗候选;以及IVX-411,一种具有SARS-CoV-2靶标的原始受体结合结构域(RBD)序列抗原,正处于1/2期临床试验。该公司成立于2017年,总部位于华盛顿州西雅图。
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《塔尔苏斯医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tarsus制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧